Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | VIR |
---|---|---|
09:32 ET | 11822 | 9.66 |
09:34 ET | 2000 | 9.54 |
09:36 ET | 3988 | 9.58 |
09:38 ET | 1700 | 9.55 |
09:39 ET | 4987 | 9.62 |
09:41 ET | 2000 | 9.585 |
09:43 ET | 1978 | 9.63 |
09:45 ET | 1904 | 9.68 |
09:48 ET | 1590 | 9.685 |
09:50 ET | 4351 | 9.7 |
09:52 ET | 4278 | 9.65 |
09:54 ET | 1336 | 9.63 |
09:56 ET | 3976 | 9.6565 |
09:57 ET | 7162 | 9.66 |
09:59 ET | 2474 | 9.72 |
10:01 ET | 5720 | 9.69 |
10:03 ET | 2488 | 9.685 |
10:06 ET | 900 | 9.68 |
10:08 ET | 1422 | 9.6444 |
10:10 ET | 700 | 9.63 |
10:12 ET | 1530 | 9.605 |
10:14 ET | 900 | 9.59 |
10:15 ET | 700 | 9.58 |
10:17 ET | 6769 | 9.6 |
10:19 ET | 2061 | 9.595 |
10:21 ET | 516 | 9.6 |
10:24 ET | 1539 | 9.6 |
10:26 ET | 1900 | 9.61 |
10:28 ET | 1379 | 9.5901 |
10:30 ET | 2669 | 9.62 |
10:32 ET | 2561 | 9.6 |
10:33 ET | 403 | 9.6099 |
10:35 ET | 2412 | 9.59 |
10:37 ET | 300 | 9.58 |
10:39 ET | 601 | 9.59 |
10:42 ET | 1400 | 9.55 |
10:44 ET | 700 | 9.55 |
10:46 ET | 6060 | 9.55 |
10:48 ET | 1806 | 9.56 |
10:50 ET | 100 | 9.56 |
10:51 ET | 2015 | 9.54 |
10:53 ET | 539 | 9.54 |
10:55 ET | 2200 | 9.55 |
10:57 ET | 1821 | 9.569 |
11:00 ET | 2012 | 9.5582 |
11:02 ET | 300 | 9.555 |
11:04 ET | 1432 | 9.54 |
11:06 ET | 1284 | 9.53 |
11:08 ET | 6960 | 9.53 |
11:09 ET | 11701 | 9.485 |
11:11 ET | 300 | 9.49 |
11:13 ET | 6278 | 9.5 |
11:15 ET | 2302 | 9.5 |
11:18 ET | 5482 | 9.49 |
11:20 ET | 1996 | 9.48 |
11:22 ET | 100 | 9.48 |
11:24 ET | 200 | 9.46 |
11:26 ET | 1465 | 9.46 |
11:27 ET | 1000 | 9.46 |
11:29 ET | 2044 | 9.46 |
11:31 ET | 895 | 9.45 |
11:33 ET | 1571 | 9.44 |
11:36 ET | 950 | 9.445 |
11:38 ET | 7340 | 9.43 |
11:40 ET | 1733 | 9.445 |
11:42 ET | 1800 | 9.445 |
11:44 ET | 7927 | 9.45 |
11:45 ET | 250 | 9.445 |
11:47 ET | 300 | 9.44 |
11:49 ET | 200 | 9.445 |
11:51 ET | 1494 | 9.44 |
11:54 ET | 400 | 9.445 |
11:56 ET | 768 | 9.44 |
11:58 ET | 4576 | 9.455 |
12:00 ET | 4775 | 9.45 |
12:02 ET | 313 | 9.44 |
12:03 ET | 100 | 9.4489 |
12:05 ET | 400 | 9.445 |
12:07 ET | 300 | 9.445 |
12:09 ET | 1000 | 9.435 |
12:12 ET | 8448 | 9.4 |
12:14 ET | 4135 | 9.36 |
12:16 ET | 5694 | 9.37 |
12:18 ET | 9471 | 9.4 |
12:20 ET | 2452 | 9.4 |
12:21 ET | 1428 | 9.4 |
12:23 ET | 400 | 9.39 |
12:25 ET | 8505 | 9.4 |
12:27 ET | 915 | 9.4 |
12:30 ET | 6525 | 9.39 |
12:32 ET | 6851 | 9.4 |
12:34 ET | 1200 | 9.4 |
12:36 ET | 1648 | 9.385 |
12:38 ET | 3329 | 9.39 |
12:39 ET | 200 | 9.38 |
12:41 ET | 1400 | 9.37 |
12:43 ET | 1300 | 9.37 |
12:45 ET | 13988 | 9.4 |
12:48 ET | 600 | 9.4 |
12:50 ET | 600 | 9.4 |
12:52 ET | 1191 | 9.39 |
12:54 ET | 800 | 9.39 |
12:56 ET | 2565 | 9.39 |
12:57 ET | 2135 | 9.38 |
12:59 ET | 100 | 9.38 |
01:01 ET | 200 | 9.38 |
01:03 ET | 400 | 9.379 |
01:06 ET | 6046 | 9.4 |
01:08 ET | 200 | 9.395 |
01:10 ET | 200 | 9.4 |
01:12 ET | 400 | 9.39 |
01:14 ET | 400 | 9.4 |
01:15 ET | 1291 | 9.4 |
01:17 ET | 7800 | 9.4 |
01:19 ET | 2485 | 9.4 |
01:21 ET | 950 | 9.4 |
01:24 ET | 2843 | 9.39 |
01:26 ET | 221 | 9.39 |
01:28 ET | 2037 | 9.37 |
01:30 ET | 24179 | 9.34 |
01:32 ET | 978 | 9.35 |
01:33 ET | 14627 | 9.33 |
01:35 ET | 4252 | 9.32 |
01:37 ET | 500 | 9.31 |
01:39 ET | 1950 | 9.32 |
01:42 ET | 9521 | 9.3053 |
01:44 ET | 3095 | 9.31 |
01:46 ET | 3708 | 9.3 |
01:48 ET | 12615 | 9.26 |
01:50 ET | 11572 | 9.24 |
01:51 ET | 7789 | 9.25 |
01:53 ET | 206443 | 9.24 |
01:55 ET | 1044 | 9.26 |
01:57 ET | 3208 | 9.235 |
02:00 ET | 700 | 9.24 |
02:02 ET | 700 | 9.24 |
02:04 ET | 4591 | 9.23 |
02:06 ET | 6293 | 9.2 |
02:08 ET | 7366 | 9.25 |
02:09 ET | 1860 | 9.25 |
02:11 ET | 1553 | 9.251 |
02:13 ET | 9317 | 9.26 |
02:15 ET | 3302 | 9.26 |
02:18 ET | 15628 | 9.3 |
02:20 ET | 9481 | 9.27 |
02:22 ET | 100 | 9.31 |
02:24 ET | 10594 | 9.22 |
02:27 ET | 1837 | 9.245 |
02:29 ET | 1143 | 9.24 |
02:31 ET | 2300 | 9.21 |
02:33 ET | 668 | 9.21 |
02:36 ET | 1900 | 9.21 |
02:38 ET | 15484 | 9.2 |
02:40 ET | 300 | 9.21 |
02:42 ET | 14591 | 9.23 |
02:44 ET | 14841 | 9.19 |
02:45 ET | 1948 | 9.2 |
02:47 ET | 490 | 9.2 |
02:49 ET | 400 | 9.19 |
02:51 ET | 14829 | 9.19 |
02:54 ET | 1945 | 9.2 |
02:56 ET | 10347 | 9.2 |
02:58 ET | 2694 | 9.2063 |
03:00 ET | 10695 | 9.18 |
03:02 ET | 3407 | 9.19 |
03:03 ET | 2315 | 9.199 |
03:05 ET | 5759 | 9.19 |
03:07 ET | 1100 | 9.195 |
03:09 ET | 2348 | 9.1925 |
03:12 ET | 7341 | 9.2 |
03:14 ET | 23400 | 9.18 |
03:16 ET | 79253 | 9.095 |
03:18 ET | 51473 | 9.05 |
03:20 ET | 27013 | 9.05 |
03:21 ET | 17407 | 9.0599 |
03:23 ET | 508585 | 9.02 |
03:25 ET | 2046 | 9.075 |
03:27 ET | 27075 | 9.03 |
03:30 ET | 43699 | 9.02 |
03:32 ET | 15183 | 9.05 |
03:34 ET | 6734 | 9.06 |
03:36 ET | 2500 | 9.08 |
03:38 ET | 9508 | 9.04 |
03:39 ET | 19240 | 9.1 |
03:41 ET | 38061 | 9.16 |
03:43 ET | 37918 | 9.17 |
03:45 ET | 9415 | 9.185 |
03:48 ET | 26274 | 9.15 |
03:50 ET | 14708 | 9.155 |
03:52 ET | 36973 | 9.17 |
03:54 ET | 24702 | 9.195 |
03:56 ET | 22861 | 9.24 |
03:57 ET | 25519 | 9.23 |
03:59 ET | 118004 | 9.18 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Vir Biotechnology Inc | 1.3B | -2.3x | --- |
Prothena Corporation PLC | 1.1B | -6.3x | --- |
Immatics NV | 1.3B | -12.5x | --- |
Ardelyx Inc | 1.5B | -21.8x | --- |
Arcus Biosciences Inc | 1.5B | -5.2x | --- |
Arvinas Inc | 1.8B | -4.1x | --- |
Vir Biotechnology, Inc. is an immunology company, which is focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions. The Company's clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). It also has several preclinical candidates in its pipeline including those targeting influenza A and B, COVID-19, respiratory syncytial virus and human metapneumovirus (RSV and MPV), and human papillomavirus (HPV). The Company's pipeline includes VIR-1949, VIR-7229, VIR-2981, VIR-8190, and HIV Cure. It also engaged in developing tobevibart, a monoclonal antibody also known as VIR-3434, and Elebsiran, an siRNA also known as VIR-2218, for the treatment and suppression of chronic HDV. Its Elebsiran is an investigational HBV-targeted siRNA that reduces HBsAg, a protein which is required for the HDV viral life cycle.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $1.3B |
---|---|
Revenue (TTM) | $79.6M |
Shares Outstanding | 136.1M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.49 |
EPS | $-4.01 |
Book Value | $11.80 |
P/E Ratio | -2.3x |
Price/Sales (TTM) | 16.7 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -780.18% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.